Quercetin Inhibits KBM7R Cell Proliferation through Wnt/-Catenin Signaling.

Evid Based Complement Alternat Med

Institute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.

Published: June 2022

Background: Tyrosine kinase inhibitors could treat chronic myelogenous leukemia (CML) effectively, but they have no effect on patients with T315I mutation. It is necessary to find drugs to overcome the resistance. Quercetin (Qu) is a kind of bioflavonoid with an antitumor effect. In this study, we observed the effect of Qu on proliferation and Wnt/-catenin pathway in KBM7R cells, an imatinib-resistant cell with T315I mutation.

Methods: The IC of Qu was detected by trypan blue staining. The KBM7R cell apoptosis and cycle were detected through the method of flow cytometry (FCM). The expression of the related mRNA and protein was evaluated by means of an RT-PCR assay and western blot in KBM7 (sensitive to IM) and KBM7R cells.

Results: These results showed that in the KBM7R cell, the proliferation inhibition effect was increased after 48 h administration with different Qu concentrations. The IC to Qu was 241.7 mol/L. The different doses of Qu (50, 100, and 200 mol/L) would raise apoptosis and depress the cell cycle at the G phase. Dealing with a median Qu concentration (100 mol/L) for 48 h, the mRNA and the protein level of caspase-3, caspase-8, and caspase-9 along with p21 and p27 raised compared with the control. The median concentration of Qu could inhibit both the mRNA and protein levels of GSK-3, -catenin, and Lef-1 in the Wnt/-catenin signal pathway and also the downstream targets PPAR- and cyclin D1 in both KBM7 and KBM7R cells.

Conclusions: Our findings suggest that Qu could inhibit proliferation, induce apoptosis, and arrest the cell cycle on IM-resistant KBM7R cells with T315I mutation. And this effect could be related with the inhibition of the Wnt/-catenin signal pathway and downstream targets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249478PMC
http://dx.doi.org/10.1155/2022/1378976DOI Listing

Publication Analysis

Top Keywords

kbm7r cell
12
mrna protein
12
cell proliferation
8
proliferation wnt/-catenin
8
t315i mutation
8
kbm7r cells
8
cell cycle
8
median concentration
8
wnt/-catenin signal
8
signal pathway
8

Similar Publications

Quercetin Inhibits KBM7R Cell Proliferation through Wnt/-Catenin Signaling.

Evid Based Complement Alternat Med

June 2022

Institute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin 150010, Heilongjiang, China.

Background: Tyrosine kinase inhibitors could treat chronic myelogenous leukemia (CML) effectively, but they have no effect on patients with T315I mutation. It is necessary to find drugs to overcome the resistance. Quercetin (Qu) is a kind of bioflavonoid with an antitumor effect.

View Article and Find Full Text PDF

Background: Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a therapy target of cancer. We aimed to confirm the effect of dual PI3K/mTOR inhibitor NVP-BEZ235 on proliferation, apoptosis, and autophagy of chronic myelogenous leukemia (CML) cells and sensitivity of tyrosine kinase inhibitor in vitro.

Methods: Two human CML cell lines, K562 and KBM7R (T315I mutant strain), were used.

View Article and Find Full Text PDF

Adaphostin is a tyrphostin that was designed to inhibit Bcr/Abl tyrosine kinase by altering the binding site of peptide substrates rather than that of adenosine triphosphate, a known mechanism of imatinib mesylate (IM). However, it has been shown that adaphostin-mediated cytotoxicity is dependent on oxidant production and does not require Bcr/Abl. We have tested adaphostin against both Philadelphia chromosome (Ph)-positive (K562, KBM5, KBM5-R [IM resistant KBM5], KBM7, and KBM7-R [IM-resistant KBM7]) and Ph-negative (OCI/AML2 and OCI/AML3) cells, and against cells from patients with chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).

View Article and Find Full Text PDF

The in vitro and in vivo activity of a deoxycytidine analogue, troxacitabine, alone or in combination with imatinib mesylate (IM), was evaluated against human chronic myeloid leukaemia (CML) cell lines both sensitive (KBM5 and KBM7) and resistant (KBM5-R and KBM7-R) to IM. These cell lines differ in their sensitivity to IM but all showed similar sensitivity to treatment with troxacitabine (IC50 = 0.5-1 micromol/l).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!